<DOC>
	<DOCNO>NCT00195741</DOCNO>
	<brief_summary>The purpose study determine whether Depakote ER safe effective reduction occurrence migraine headaches adolescent .</brief_summary>
	<brief_title>The Safety Efficacy Divalproex Sodium Extended-Release Tablets Migraine Prophylaxis : A Study Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Subject subject 's legal representative voluntarily sign date IRBapproved informed assent form IRBapproved inform consent form , respectively , studyspecific procedure test perform , include discontinuation prohibit medication Subject male nonpregnant , nonlactating female ; Subject 12 17 year age , inclusive , randomization ; Subject weigh 77 lb ( i.e. , 35 kg ) 220 lb ( i.e. , 100 kg ) inclusive ; Subject currently migraine headache diagnose accord International Headache Society ( IHS ) diagnostic criterion occur average frequency least 3 , 12 , migraine headache per month 3 month prior screen . Migraine headache separate headachefree interval &lt; 48 hour consider one migraine headache assess criterion ; Subject 's initial onset migraine headache precedes Screening Visit least 12 month ; Subject judge generally good health base result medical history , physical examination , 12lead electrocardiogram ( ECG ) , laboratory profile . When Screening Baseline Visits combine described Section 5.1 , continue participation Baseline Phase contingent upon laboratory ECG result . Any repeat laboratory test must complete consultation Abbott Medical Monitor prior randomization . Experimental Phase The following criterion define eligibility subject enrollment Experimental Phase subsequent randomization study drug assignment : Subject experience least 3 , 12 , migraine headache ( separate headachefree interval least 48 hour ) , diagnose accord IHS diagnostic criteria,6 4week Baseline Phase study ; Subject still eligible study base Baseline Phase inclusion criterion . Exclusion Criteria Baseline Phase History allergic reaction significant sensitivity valproate similar drug ; History noncompliance medication medical instruction ; Previously randomize study ; Recent ( previous 6 month ) history drug and/or alcohol abuse positive urine drug screen , Screening Visit , drug abuse ( e.g. , amphetamine , barbiturate , benzodiazepine , cocaine , opiates , phencyclidine [ PCP ] ) ; Female , childbearing potential , use effective method birth control ( e.g. , total sexual abstinence contraceptive ) ; History cluster headache ( see Appendix G , Diagnostic Criteria Headaches ) , seizure disorder , suspect history seizure disorder ; History headaches type occur 15 day per month , average , use medication excessively headache ( e.g. , regularly take medication 10 day per month ) ; Failed 2 adequate regimen prophylactic antimigraine medication , include antiepilepsy drug ( ) ( e.g. , gabapentin , topiramate ) 1 adequate regimen valproate ; Use prophylactic antimigraine medication within period equivalent &lt; 5 halflives medication enter Baseline Phase ; Daily use analgesic , ergotamine preparation , nonsteroidal anti inflammatory agent ( see Appendix J , Examples Prohibited Medications ) ; Use follow medication class specific drug list : anticoagulant antidepressant antiepileptic antipsychotic benzodiazepine betaadrenergic block agent calcium channel antagonist cimetidine corticosteroid cyproheptadine erythromycin ethosuximide lithium salt methysergide phenobarbital pemoline rifampin tolbutamide zidovudine Use valproate within 30 day prior screen ; Use aspirin and/or aspirincontaining product ( e.g. , Excedrin Migraine , PeptoBismol , Alka Seltzer ) within 5 halflives prior randomization time Experimental Phase study ; Use stimulants AttentionDeficit Hyperactivity Disorder ( ADHD ) ( exception pemoline , Cylert ) stable treatment regimen establish minimum least 2 month prior screen treatment regimen establish risk change sometime trial ; Any serious medical psychiatric disorder ( ) may confound interpretation result study ; Central nervous system ( CNS ) neoplasm , CNS infection , demyelinate disease , degenerative neurological disease , progressive CNS disease ; History encephalopathy , hepatitis , pancreatitis , ureacycle disorder underlie condition/disease , might interfere study drug absorption completion study drug therapy evaluation throughout duration trial ; Screening laboratory result indicate presence Hepatitis B surface antigen ( HBSAG ) , Hepatitis C antibody known history positive test result HIV ; Screening laboratory result indicate : Platelet count &lt; /= 100,000/uL ALT AST &gt; /= 2 time Upper Limit Normal ( ULN ) ; Receipt investigational drug within 30 day prior study drug administration schedule receive investigational drug anytime study ; For reason , subject consider investigator unsuitable candidate receive Depakote participate study . Experimental Phase Subjects exhibit follow ineligible : A positive pregnancy test result Study Day 1 ; Failure properly maintain Headache Medication Diary , Baseline phase , extent headache occurrence determine , due noncompliance ; Excessive use symptomatic medication ( ) Baseline Phase ( e.g. , regularly take medication 10 day per month ) ; Ineligibility study base Baseline Phase exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Depakote ER</keyword>
</DOC>